In an early trial published Oct. 23, 2026, in Nature Medicine, invikafusp alfa, a drug that activates specific T cells, shrank tumors in 14.8% of patients at the best doses, including some 'cold' tumors that usually resist immunotherapy.
A study published Oct. 28, 2026, in Science Translational Medicine, combining a phase 2 trial of 106 patients with tumor data from 152 patients, found that B cells and antibody responses were linked to complete, lasting responses to immunotherapy in…